{"id":"https://openalex.org/W2016013480","doi":"https://doi.org/10.1097/00002826-199712000-00005","title":"Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy Volunteers","display_name":"Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy Volunteers","publication_year":1997,"publication_date":"1997-12-01","ids":{"openalex":"https://openalex.org/W2016013480","doi":"https://doi.org/10.1097/00002826-199712000-00005","mag":"2016013480","pmid":"https://pubmed.ncbi.nlm.nih.gov/9403227"},"language":"en","primary_location":{"id":"doi:10.1097/00002826-199712000-00005","doi":"https://doi.org/10.1097/00002826-199712000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-199712000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111626346","display_name":"Greg Sedek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G. S\u00eadek","raw_affiliation_strings":["Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, USA","Switzerland","U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, USA","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Switzerland","institution_ids":[]},{"raw_affiliation_string":"U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110032422","display_name":"Karin M. Jorga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"K. Jorga","raw_affiliation_strings":["Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","Quintiles Phase I Services, Lenexa, Kansas, U.S.A","and Vanderbilt University, Nashville, Tennessee, U.S.A","Switzerland","U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Quintiles Phase I Services, Lenexa, Kansas, U.S.A","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"and Vanderbilt University, Nashville, Tennessee, U.S.A","institution_ids":["https://openalex.org/I200719446"]},{"raw_affiliation_string":"Switzerland","institution_ids":[]},{"raw_affiliation_string":"U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109307026","display_name":"Monique Schmitt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"M. Schmitt","raw_affiliation_strings":["Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","Quintiles Phase I Services, Lenexa, Kansas, U.S.A","and Vanderbilt University, Nashville, Tennessee, U.S.A","Switzerland","U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Quintiles Phase I Services, Lenexa, Kansas, U.S.A","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"and Vanderbilt University, Nashville, Tennessee, U.S.A","institution_ids":["https://openalex.org/I200719446"]},{"raw_affiliation_string":"Switzerland","institution_ids":[]},{"raw_affiliation_string":"U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111826028","display_name":"Richard S. Burns","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"R. S. Burns","raw_affiliation_strings":["Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","Quintiles Phase I Services, Lenexa, Kansas, U.S.A","and Vanderbilt University, Nashville, Tennessee, U.S.A","Switzerland","U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Quintiles Phase I Services, Lenexa, Kansas, U.S.A","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"and Vanderbilt University, Nashville, Tennessee, U.S.A","institution_ids":["https://openalex.org/I200719446"]},{"raw_affiliation_string":"Switzerland","institution_ids":[]},{"raw_affiliation_string":"U.S.A","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042149219","display_name":"Phillip T. Leese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"P. Leese","raw_affiliation_strings":["Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","Quintiles Phase I Services, Lenexa, Kansas, U.S.A","and Vanderbilt University, Nashville, Tennessee, U.S.A","Switzerland","U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Hoffmann-La Roche, Nutley, New Jersey, U.S.A., and Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Quintiles Phase I Services, Lenexa, Kansas, U.S.A","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"and Vanderbilt University, Nashville, Tennessee, U.S.A","institution_ids":["https://openalex.org/I200719446"]},{"raw_affiliation_string":"Switzerland","institution_ids":[]},{"raw_affiliation_string":"U.S.A","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.9881,"has_fulltext":false,"cited_by_count":40,"citation_normalized_percentile":{"value":0.93243585,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"20","issue":"6","first_page":"531","last_page":"541"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tolcapone","display_name":"tolcapone","score":1.0},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.9610000252723694},{"id":"https://openalex.org/keywords/carbidopa","display_name":"carbidopa","score":0.9919999837875366},{"id":"https://openalex.org/keywords/levodopa-carbidopa","display_name":"levodopa/carbidopa","score":0.7429999709129333},{"id":"https://openalex.org/keywords/catechol-o-methyltransferase-inhibitors","display_name":"catechol-O-methyltransferase inhibitors","score":0.8790000081062317},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.6970000267028809},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.8740000128746033},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7509999871253967},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5210000276565552}],"concepts":[{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.9030866622924805},{"id":"https://openalex.org/C2776754145","wikidata":"https://www.wikidata.org/wiki/Q71133637","display_name":"Carbidopa","level":5,"score":0.8787341713905334},{"id":"https://openalex.org/C2779026782","wikidata":"https://www.wikidata.org/wiki/Q818165","display_name":"Benserazide","level":5,"score":0.837570309638977},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7363696694374084},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6278393268585205},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.6250627040863037},{"id":"https://openalex.org/C2776976799","wikidata":"https://www.wikidata.org/wiki/Q416444","display_name":"Entacapone","level":5,"score":0.5735505819320679},{"id":"https://openalex.org/C185361966","wikidata":"https://www.wikidata.org/wiki/Q94291140","display_name":"Catechol-O-methyl transferase","level":4,"score":0.562389612197876},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5472797751426697},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5456583499908447},{"id":"https://openalex.org/C2780405171","wikidata":"https://www.wikidata.org/wiki/Q629444","display_name":"Dyskinesia","level":4,"score":0.4518338441848755},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4010372757911682},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3797406554222107},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3501587510108948},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3238310217857361},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3090789020061493},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.2948548197746277},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077867","descriptor_name":"Tolcapone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D001577","descriptor_name":"Benzophenones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001577","descriptor_name":"Benzophenones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001711","descriptor_name":"Biotransformation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009596","descriptor_name":"Nitrophenols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002826-199712000-00005","doi":"https://doi.org/10.1097/00002826-199712000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-199712000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:9403227","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9403227","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical neuropharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3190928834","https://openalex.org/W2036056358","https://openalex.org/W1985417541","https://openalex.org/W2113689256","https://openalex.org/W1965714500","https://openalex.org/W2018545901","https://openalex.org/W2090089396","https://openalex.org/W1998323566","https://openalex.org/W2007127172","https://openalex.org/W2069643254"],"abstract_inverted_index":{"Tolcapone":[0,136],"(Ro":[1],"40-7592)":[2],"is":[3,10],"a":[4,26,31,113,117],"novel":[5],"inhibitor":[6,36],"of":[7,19,28,51,67,72,83,91,120,147],"catechol-O-methyltransferase":[8],"that":[9],"being":[11],"developed":[12],"for":[13],"clinical":[14],"use":[15],"in":[16,60,112,116],"the":[17,49,79,134,138,141,154,166],"treatment":[18],"Parkinson's":[20],"disease":[21],"as":[22],"add-on":[23],"therapy":[24],"to":[25,47,77],"combination":[27],"levodopa":[29,58,73,148,161],"and":[30,69,76,81,99,131,145],"peripheral":[32],"amino":[33],"acid":[34],"decarboxylase":[35],"(benserazide":[37],"or":[38,87],"carbidopa).":[39],"The":[40,157],"current":[41],"single-blind,":[42],"randomized":[43],"study":[44],"was":[45,102,110,163],"designed":[46],"evaluate":[48],"effect":[50,159],"tolcapone":[52,88],"compared":[53],"with":[54,105,165],"placebo":[55,132],"on":[56,128,133,160],"plasma":[57,142],"concentrations":[59],"healthy":[61],"volunteers":[62],"concomitantly":[63],"receiving":[64],"25":[65],"mg":[66,71,101],"carbidopa":[68],"100":[70],"(Sinemet":[74],"25-100)":[75],"assess":[78],"tolerability":[80],"safety":[82],"this":[84],"combination.":[85],"Placebo":[86],"at":[89,173],"doses":[90],"5,":[92],"10,":[93],"25,":[94],"50,":[95],"100,":[96],"200,":[97],"400,":[98],"800":[100],"coadministered":[103],"orally":[104],"Sinemet":[106],"25-100.":[107],"Each":[108],"dose":[109],"tested":[111],"crossover":[114],"fashion":[115],"new":[118],"group":[119],"six":[121],"participants":[122],"who":[123],"each":[124],"received":[125],"active":[126],"drug":[127],"one":[129],"occasion":[130],"other.":[135],"increased":[137],"area":[139],"under":[140],"concentration-time":[143],"curve":[144],"half-life":[146,162],"approximately":[149],"twofold,":[150],"without":[151],"appreciably":[152],"increasing":[153],"peak":[155],"concentration.":[156],"maximum":[158],"observed":[164],"200-mg":[167],"dose.":[168],"Adverse":[169],"effects":[170],"were":[171],"minor":[172],"all":[174],"doses.":[175]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}